NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01578707,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT01578707,RESONATE™,COMPLETED,The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL),YES,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,DRUG: ofatumumab|DRUG: ibrutinib,"PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013, The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines., Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.","Overall Response Rate (ORR) by Independent Review Committee (IRC), Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013, About 18 months after the first subject was enrolled|OS (Overall Survival), OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm, OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up|Rate of Sustained Hemoglobin and Platelet Improvement, Proportion of subjects with hemoglobin (HgB) increase \>=20 g/L and platelet (PLT) increase \>=50% over baseline continuously for \>=56 days without blood transfusions or growth factors., From study initiation to study closure, including up to 6 years of study follow-up","Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up, Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up, From study initiation to study closure, including up to 6 years of study follow-up|Overall Response Rate (ORR) by Investigator, Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up, From study initiation to study closure, including up to 6 years of study follow-up",Pharmacyclics LLC.,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,391,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,PCYC-1112-CA|2012-000694-23,2012-06,2013-11,2018-10-25,2012-04-17,2015-10-12,2019-12-18,"Site #408, La Jolla, California, 92093-0698, United States|Site #377, Los Angeles, California, 90095, United States|Site #403, Santa Maria, California, 93454, United States|Site #038, Stanford, California, 94035, United States|Site #411, Norwalk, Connecticut, 06856, United States|Site #107, Marietta, Georgia, 30060, United States|Site # 379, Evansville, Indiana, 47713, United States|Site # 390, Boston, Massachusetts, 02114, United States|Site # 391, Boston, Massachusetts, 02115, United States|Site # 349, Boston, Massachusetts, 02215, United States|Site # 130, Detroit, Michigan, 48201, United States|Site # 406, Rochester, Minnesota, 55901, United States|Site # 059, New Brunswick, New Jersey, 08903, United States|Site # 350, New Hyde Park, New York, 11042, United States|Site # 200, New York, New York, 10065, United States|Site # 127, Rochester, New York, 14642-0001, United States|Site # 197, Cincinnati, Ohio, 45291, United States|Site # 217, Columbus, Ohio, 43210, United States|Site # 402, Philadelphia, Pennsylvania, 19104, United States|Site # 396, Greenville, South Carolina, 29601, United States|Site # 410, Nashville, Tennessee, 37232-5505, United States|Site # 032, Houston, Texas, 77030, United States|Site # 381, Laredo, Texas, 78041, United States|Site # 210, Charlottesville, Virginia, 22908, United States|Site # 404, Seattle, Washington, 98109, United States|Site # 500, St. Leonards, New South Wales, 2065, Australia|Site # 503, Brisbane, Queensland, 4102, Australia|Site # 199, East Melbourne, Victoria, 3002, Australia|Site # 501, Fitzroy, Victoria, 3109, Australia|Site # 502, Nedlands, Western Australia, 6009, Australia|Site # 509, Graz, 8036, Austria|Site # 508, Linz, 4010, Austria|Site # 504, Salzburg, 5020, Austria|Site # 505, Vienna, A-1090, Austria|Site # 506, Wein, 1160, Austria|Site # 507, Wels, A-4600, Austria|Site # 393, Antwerpen, 2060, Belgium|Site # 519, Argenteuil, 95107, France|Site # 511, Bobigny, 93009, France|Site # 515, Bordeaux, 33076, France|Site # 516, Caen, 14033, France|Site # 513, Clermont Ferrand, 63100, France|Site # 510, Marseille, 13273, France|Site # 520, Nantes, 44000, France|Site # 518, Rennes, 35033, France|Site # 517, Vandœuvre-lès-Nancy, 54511, France|Site # 570, Dublin, 8, Ireland|Site # 528, Dublin, 9, Ireland|Site # 096, Galway, Ireland|Site # 522, Milano, 20089, Italy|Site # 523, Milano, 20132, Italy|Site # 526, Milano, 20162, Italy|Site # 524, Modena, 41124, Italy|Site # 527, Padova, 35128, Italy|Site # 529, Gdansk, 80-952, Poland|Site # 531, Lodz, 93-510, Poland|Site # 535, Barcelona, 08025, Spain|Site # 534, Barcelona, 08035, Spain|Site # 533, Barcelona, 08036, Spain|Site # 539, Coruna, 15006A, Spain|Site # 540, Madrid, 28033, Spain|Site # 537, Madrid, 28050, Spain|Site # 536, Madrid, 28222, Spain|Site # 538, Pamplona, 31008, Spain|Site # 549, Colchester, Essex, CO4 5JL, United Kingdom|Site # 543, Sutton, Surrey, SM2 5PT, United Kingdom|Site # 551, Bournemouth, BH7 7DW, United Kingdom|Site # 553, Canterbury, CT1 3NG, United Kingdom|Site # 546, Cardiff, CF14 4XW, United Kingdom|Site # 554, Headington, OX3 7LJ, United Kingdom|Site # 550, Leeds, LS9 7TF, United Kingdom|Site # 552, Liverpool, L7 8XP, United Kingdom|Site # 544, London, SE5 9RS, United Kingdom|Site # 548, Nottingham, NG5 1PB, United Kingdom|Site # 545, Southampton, SO16 6YD, United Kingdom|Site # 541, Withington, M20 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/07/NCT01578707/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/07/NCT01578707/SAP_001.pdf"
